VickyMakkerMD

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Makker

Dr. Vicky Makker is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from University of Florida College of Medicine and has been in practice 14 years. Dr. Makker accepts several types of health insurance, listed below. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(313) 447-0624

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Florida College of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2006 - 2025

Clinical Trials

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA Start of enrollment: 2014 Sep 01
Unknown status
Phase 2
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Start of enrollment: 2017 Jan 01
Completed
Phase 2
A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients Start of enrollment: 2017 Aug 11
Active, not recruiting
Not Applicable
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer Start of enrollment: 2018 Aug 21
Active, not recruiting
Phase 2
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma Start of enrollment: 2021 Dec 23
Recruiting
Phase 2
Roles: Principal Investigator, Contact
ZW25 in Women With Endometrial Cancers Start of enrollment: 2020 Aug 12
Completed
Phase 2
Roles: Principal Investigator, Contact
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Start of enrollment: 2022 Apr 22
Active, not recruiting
Phase 1
Roles: Principal Investigator
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer Start of enrollment: 2023 Jan 10
Recruiting
Early Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

42 citations
Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers.
Harini Veeraraghavan, Claire F. Friedman, Deborah F. DeLair, Josip Nincevic, Yuki Himoto
Scientific Reports. 2020-10-20
27 citations
Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer
Sarah A. Milgrom, Marisa A. Kollmeier, Nadeem R. Abu-Rustum, Vicky Makker, Ginger J. Gardner
Gynecologic Oncology. 2013-07-01
332 citations
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew W. Rasco, Nicholas J. Vogelzang, Marcia S. Brose, Allen Lee Cohn
The Lancet. Oncology. 2019-05-01

Journal Articles

Case Report Next-Generation Sequencing Based Detection of Germline and Somatic Alterations in a Patient with Four Metachronous Primary Tumors
Joshua K Sabari, Gulisa Turashvili, Vicky Makker, Darragh F Halpenny, ScienceDirect

Lectures

A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
2019 ASCO Annual Meeting - 6/1/2019
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Implementing a Burnout Prevention Program Among Medical Oncology Fellows: Challenges, Successes, and Opportunities
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

For Advanced Endometrial Cancer, Chemotherapy plus Immunotherapy Improves OutcomesMarch 28th, 2023
Gynecologic Cancer Clinicians and Researchers Recognized at SGO 2022 Annual Meeting on Women’s CancerMarch 21st, 2022
ENGOT and the GOG Foundation, Inc. (GOG) Announce Promising First Results of New Maintenance Therapy for Advanced or Recurrent Endometrial CancerMarch 17th, 2022
Join now to see all

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment